Background: Insulin resistance occurs both in obesity and in Cushing’s syndrome suggesting a pathogenetic role of cortisol in insulin-resistant obese subjects. Methods: We examined serum cortisol in 81 insulin-resistant (homeostasis model assessment (HOMA) >4) obese children (age in median 12 years) and 151 obese children without insulin resistance (HOMA ≤4) (age in median 10 years) and compared these to cortisol of 83 healthy children of normal weight (age in median 12 years). Multivariate linear regression analysis was conducted for the dependent variable insulin resistance (HOMA), including weight status (BMI), age, gender, pubertal stage and cortisol concentration as independent variables. Furthermore, we analyzed cortisol and insulin resistance in 45 obese children with significant weight loss (reduction in SDS-BMI ≧0.5) and in 109 obese children without significant weight loss (reduction in SDS-BMI <0.5) over the time period of 1 year. Results: Cortisol was significantly (p = 0.006) higher in obese insulin-resistant children (median 14.6 µg/dl) compared to those of normal weight (median 11.4 µg/dl) or obese without insulin resistance (median 11.7 µg/dl). Insulin resistance was significantly influenced by weight status (BMI), age and cortisol using multivariate linear regression analysis. A reduction in overweight showed a significant decrease in cortisol (p = 0.005) and insulin resistance (p = 0.002) in insulin-resistant children, whilst there were no significant changes in children not reducing their overweight and in non-insulin-resistant children. Conclusions: Cortisol was moderately increased in insulin-resistant, obese children and related to insulin resistance. Weight reduction led to a decrease in cortisol and insulin resistance. These facts point to an association between cortisol and insulin resistance in obesity.

Keywords:
Cortisol, Insulin resistance, Obesity, Children, Weight loss
1.
Bleicher M, Hogel J, Wudy S, Wabitsch M, Homoki J, Sorgo W, Heinze E: Insulin resistance (HOMA) in relation to plasma cortisol, IGF-I and IGFBP-3. A study in normal short-statured and GH-deficient children. Horm Res 2002;58:229–232.
2.
Bähr V, Pfeiffer AF, Diederich S: The metabolic syndrome X and peripheral cortisol synthesis. Exp Clin Endocrinol Diabetes 2002;110:313–318.
3.
Csabi G, Török K, Jeges S, Molnar D: Presence of metabolic cardiovascular syndrome in obese children. Eur J Pediatr 2000;159:91–94.
4.
Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geller F, Geiss HC, Hesse V, Hippel A, Jaeger U, Johnsen D, Korte W, Menner K, Müller G, Müller JM, Niemann-Pilatus A, Remer T, Schaefer F, Wittchen HU, Zabransky S, Zellner K, Ziegler A, Hebebrand J: Percentiles of body mass index in children and adolescents evaluated from different regional German studies. Monatsschr Kinderheilkd 2001;149:807–818.
5.
Cole TJ, Bellizzi MC, Flegal KM, Dietz WH: Establishing a standard definition for child overweight and obesity world-wide: International survey. BMJ 2000;320:1240–1243.
6.
Sippell WG, Dorr HG, Bidlingmaier F, Knorr D: Plasma levels of aldosterone, corticosterone, 11-deoxycorticosterone, progesterone, 17-hydroxyprogesterone, cortisol, and cortisone during infancy and childhood. Pediatr Res 1980;14:39–46.
7.
Blum WF, Englaro P, Hanitsch S, Juul A, Hertel NT, Müller J, Skakkebaek NE, Heiman ML, Birkett M, Attanasio AM, Kiess W, Rascher W: Plasma leptin levels in healthy children and adolescents: Dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab 1997;82:2904–2910.
8.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
9.
Kiess W, Meidert A, Dressendorfer RA, Schriever K, Kessler U, Konig A, Schwartz HP, Strasburger JC: Salivary cortisol levels throughout childhood and adolescence: Relation with age, pubertal stage, and weight. Pediatr Res 1995;37:502–506.
10.
Allard P, Delvin EE, Paradis G, Hanley JA, O’Loughlin J, Lavallee C, Levy E, Lambert M: Distribution of fasting plasma insulin, free fatty acids, and glucose concentrations and of homeostasis model assessment of insulin resistance in a representative sample of Quebec children and adolescents. Clin Chem 2003;49:644–649.
11.
Haffner SM, Gonzalez C, Miettinen H, Kennedy E, Stern M: A prospective analysis of the HOMA model. Diabetes Care 1996;19:1138–1141.
12.
Reinehr T, Kersting M, Alexy U, Andler W: Long-term follow-up of overweight children: After training, after a single consultation session and without treatment. J Pediatr Gastroenterol Nutr 2003;37:72–74.
13.
Reinehr T, Brylak K, Alexy U, Kersting M, Andler W: Predictors to success in outpatient training in obese children and adolescents. Int J Obes 2003;27:1087–1092.
14.
Reinehr T, Andler W: Changes in the atherogenic risk-factor profile according to degree of weight loss. Arch Dis Child 2004;89:419–422.
15.
American Diabetes Association: Type 2 diabetes in children and adolescents. Diab Care 2000;23:381–389.
16.
Fernandez-Real JM, Pugeat M, Emptoz-Bonneton A, Ricart W: Study of the effect of changing glucose, insulin, and insulin-like growth factor-I levels on serum corticosteroid binding globulin in lean, obese, and obese subjects with glucose intolerance. Metabolism 2001;50:1248–1252.
17.
Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S: Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Eng J Med 2002;346:802–810.
18.
Hanson RW, Reshef L: Regulation of phosphoenolpyruvate carboxykinase gene expression. Annu Rev Biochem 1997;66:581–611.
19.
Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, Spiegelman BM: Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001;413:131–138.
20.
Bujalska IJ, Kumar S, Stewart PM: Does central obesity reflect ‘Cushing’s disease of the omentum’? Lancet 1997;349:1210–1213.
21.
Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166–2170.
22.
Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM: Immunohistochemical localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues. J Pediatr 2002;141:415–420.
23.
Bujalska IJ, Walker EA, Hewison M, Stewart PM: A switch in dehydrogenase to reductase activity of 11β-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 2002;87:1205–1210.
24.
Samojlik E, Kirschner MA, Silber D, Schneider G, Ertel NH: Elevated production and metabolic clearance rates of androgens in morbidly obese women. J Clin Endocrinol Metab 1984;59:949–953.
25.
Wabitsch M, Hauner H, Heinze E, Böckmann A, Benz R, Meyer H, Teller W: Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. J Clin Endocrinol Metab 1995;80:3469–3475.
26.
Pasquali R, Cantobelli S, Casimirri F: The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab 1993;77:341–346.
27.
Pasquali R, Ambrosi B, Armanini D, Cavagnini F, Uberti ED, Del Rio G, de Pergola G, Maccario M, Mantero F, Marugo M, Rotella CM, Vettor R: Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: A dose-response study. J Clin Endocrinol Metab 2002;87:166–175.
28.
Marin P, Darin M, Amemiya T, Anderson B, Jewrn S, Bjorntop P: Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 1992;41:882–886.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.